Login to Your Account

Neurocrine Begins 5th Phase III, Gets Patent Protection Until 2020

By Brady Huggett

Wednesday, June 5, 2002
Neurocrine Biosciences Inc. kicked off its fifth Phase III trial of its insomnia product - but the first with the modified-release version - and said it was issued a patent for the chemical composition of the drug that would give the company patent exclusivity until 2020. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription